Commercial StrategyImportant updates on the PREVAIL MACE endpoint trial design, obi commercial strategy, and pipeline expansion increase conviction that NAMS is strategically executing well.
Market OpportunityThere is a substantial commercial opportunity afforded by the broad, accelerating physician preference for the comprehensive LDL+ profile of obi.
R&D DifferentiationNewAmsterdam hosted a comprehensive R&D day event that reinforced obicetrapib's differentiated 'LDL+' clinical profile, indicating potential patient benefits beyond lowering LDL-C.